Edition:
United Kingdom

People: Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

139.51USD
22 May 2019
Change (% chg)

$1.03 (+0.74%)
Prev Close
$138.48
Open
$138.00
Day's High
$140.11
Day's Low
$137.81
Volume
222,721
Avg. Vol
602,578
52-wk High
$197.00
52-wk Low
$125.84

Walsh, Matthew 

Mr. Matthew M. Walsh had been appointed as Chief Financial Officer of the Company, effective February 20, 2018. Prior to joining the Company, Mr. Walsh, 51served as Executive Vice President and Chief Financial Officer of Catalent, a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products, since 2012 and served as Senior Vice President and Chief Financial Officer of Catalent from 2008 to 2012. Prior to joining Catalent, Mr. Walsh served as President, Chief Financial Officer and Acting Chief Executive Officer of Escala Group, Inc., a global collectibles network and precious metals trader. From 1996 through 2006, Mr. Walsh held a variety of finance leadership roles at GenTek, Inc., an industrial manufacturer, including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller. Mr. Walsh is a CFA® charterholder who received a MBA from Cornell University, SC Johnson Graduate School of Management, and a Bachelor of Science in Chemical Engineering from Cornell University, College of Engineering.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --